BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
about
JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer.BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA-end-processing factor CtIP.Bcr/Abl interferes with the Fanconi anemia/BRCA pathway: implications in the chromosomal instability of chronic myeloid leukemia cells.Neutrophil Gelatinase-Associated Lipocalin (NGAL), Pro-Matrix Metalloproteinase-9 (pro-MMP-9) and Their Complex Pro-MMP-9/NGAL in Leukaemias.Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptorSerum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitorsFirst-line treatment of chronic myeloid leukaemia.Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.Loss of mutL homolog-1 (MLH1) expression promotes acquisition of oncogenic and inhibitor-resistant point mutations in tyrosine kinases.Initial diagnosis of chronic myelogenous leukemia based on quantification of M-BCR status using droplet digital PCR.How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this?FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia.ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells.Myelodysplastic syndrome (MDS)-associated cytogenetic abnormalities in pediatric chronic myelogenous leukemia.A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.Genomic instability in chronic myeloid leukemia: targets for therapy?Increased c-Myc activity and DNA damage in hematopoietic progenitors precede myeloproliferative disease in Spa-1-deficiency.Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of casesRevisiting Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Cancer: Saint or Sinner?
P2860
Q27012572-E2358BB4-01F4-4C70-91EA-E6F85D1238D1Q28249103-4EA4062C-4581-4585-B2BC-3F5F2466979BQ30010486-B14CABDD-C905-44BA-9C63-F705020DC643Q31092851-59A311D4-CD58-4CE3-B239-1910DC469B21Q33727572-0C4143FE-8DC3-421F-8796-94EC66C3D3CAQ33784347-24641890-164C-45F5-8266-22E716A6E369Q33820258-D74A3DFC-6CDF-4C3A-9DCD-0C194416AD8CQ34293414-B5B366E3-5D35-4771-8E44-75BCBCC7BFFDQ35483727-18C07175-386C-4A2E-89F3-7997B96AAC55Q36364835-8874E018-A816-42F9-8717-788CE345889CQ36612527-DE3B272D-E8DE-4F9A-A0EE-9A46905A9267Q37688465-F37003D9-A73C-4F4C-9F8B-12FAB1EE5266Q38756876-5268E345-525C-4427-A492-FD64C64541F6Q38814852-9CC71408-FA23-4C75-A6EF-1964BA18E999Q38845834-A7742C63-9BCA-4702-9E54-E577C824B1D8Q38953085-0F609EEE-EBD0-4846-9699-64C877829B7CQ39126141-CB3D8F81-B90B-4249-BFF9-D25BEA24C0D4Q40576732-996D467C-1A6E-4722-923D-E93648E8A722Q42821539-50995FC0-6DF0-47C2-AE1E-B0D646B9B5DEQ44496127-F3AE8E1B-2AA7-414B-95DF-7DE0FC0CB943Q45342289-7EEE0BB3-C2C8-4EBA-A03B-B0E1747D72A5Q53272675-68143D90-1C44-4A9C-B2FF-98340E57A8A9Q53291504-40253686-9AA5-4BCB-9003-8CCB43E86585Q54274548-5734B117-FD98-4D21-BF53-C68866C2F807Q58023808-8638DEC2-1D89-48B3-B19C-6785D675079EQ58723325-BAC53159-0950-4AA5-A50A-154FE6B13F86
P2860
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
@en
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
@nl
type
label
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
@en
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
@nl
prefLabel
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
@en
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
@nl
P2860
P356
P1433
P1476
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2010.67
P577
2010-05-06T00:00:00Z